SCHEMBL498177

SCHEMBL498177

FC[C]1CC1

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1515198 0.84
SCHEMBL497933 0.84
SCHEMBL7717442 0.81
SCHEMBL6409752 0.67
SCHEMBL21609451 0.60
SCHEMBL10276 0.46
SCHEMBL23044067 0.45
SCHEMBL2339 0.45
SCHEMBL11038950 0.41
SCHEMBL26810 0.41

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 261 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4395890-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING Remix Therapeutics Inc. (US) 2024-07-10 EP claimed
US-11655243-B2 Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists HOFFMANN-LA ROCHE INC. (US) 2023-05-23 US claimed
WO-2023034836-A1 COMPOUNDS AND METHODS FOR MODULATING SPLICING REMIX THERAPEUTICS INC. (US) 2023-03-09 WO claimed
EP-3814337-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS F. Hoffmann-La Roche AG (CH) 2021-05-05 EP claimed
US-20210115027-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS HOFFMANN-LA ROCHE INC. (US) 2021-04-22 US claimed
CN-112074513-A Pyridine and pyrazine derivatives as preferential cannabinoid 2 agonists 豪夫迈·罗氏有限公司 2020-12-11 CN claimed
EP-3478674-B1 4,6-DIAMINOQUINAZOLINES AS COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES INC (US) 2020-05-13 EP claimed
US-10577352-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2020-03-03 US claimed
WO-2020002270-A1 PYRIDINE AND PYRAZINE DERIVATIVES AS PREFERENTIAL CANNABINOID 2 AGONISTS F. HOFFMANN-LA ROCHE AG (CH) 2020-01-02 WO claimed
EP-3478674-A1 4,6-DIAMINOQUINAZOLINES AS COT MODULATORS AND METHODS OF USE THEREOF Gilead Sciences, Inc. (US) 2019-05-08 EP claimed
US-20190016705-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2019-01-17 US claimed
US-10059695-B2 Cot modulators and methods of use thereof GILEAD SCIENCES, INC. (US) 2018-08-28 US claimed
CN-104854092-B Pyridine-2-amides useful as CB2 agonists 霍夫曼-拉罗奇有限公司 2018-08-10 CN claimed
US-20180002316-A1 COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. 2018-01-04 US claimed
WO-2018005435-A1 4,6-DIAMINOQUINAZOLINES AS COT MODULATORS AND METHODS OF USE THEREOF GILEAD SCIENCES, INC. (US) 2018-01-04 WO claimed
EP-1102767-B1 SUBSTITUTED PYRAZOLE DERIVATIVES BAYER HEALTHCARE AG (DE) 2005-11-02 EP claimed
CN-1571669-A Novel combination BUYER MEDICINE AND HEALTH CARE (DE) 2005-01-26 CN claimed
US-6833364-B1 Inhibiting degradation of cyclic guanosine monophosphate; cardiovascular disorders; such as 3-(4-amino-5-cyclopropyl-pyrimidin-2-yl)-1-(2-fluorobenzyl)1H-pyrazolo-(3,4 -b)-pyridine BAYER HEALTHCARE AG (DE) 2004-12-21 US claimed
US-20040186163-A1 Novel combination BAYER HEALTHCARE AG (DE) 2004-09-23 US claimed
US-20040053915-A1 Use of stimulators of soluble guanylate cyclase for treating osteoporosis BAYER AKTIENGESELLSCHAFT (DE) 2004-03-18 US claimed